text:
Psychedelics Investing >
Hollister Biosciences Announces Third Quarter Fiscal 2021 Financial Results Including Revenue of USD $14.5M and Adjusted Ebitda of USD $1.2M
Revenue of $14.5 million increased 53% from prior year period Gross profit income of $3.5 million increased 151% from prior year period Net income was $0.4 million versus a loss of $0.6 million in prior year period Adjusted EBITDA was $1.2 million, versus a loss of $0.6 million in prior year period Maintained a strong liquidity position, including a cash & cash equivalents balance of $7.6 million an increase of ...
Revenue of $14.5 million increased 53% from prior year period
Gross profit income of $3.5 million increased 151% from prior year period
Net income was $0.4 million versus a loss of $0.6 million in prior year period
Adjusted EBITDA was $1.2 million, versus a loss of $0.6 million in prior year period
Maintained a strong liquidity position, including a cash & cash equivalents balance of $7.6 million , an increase of 300% from prior year quarter
VANCOUVER, BC , Nov. 29, 2021 /CNW/ - Hollister Biosciences Inc. (CSE: HOLL) (OTC: HSTRF) (FRANKFURT: HOB) (the " Company " or " Hollister ") today announced its financial results for the third quarter fiscal 2021 ended September 30, 2021 . All financial information is presented in U.S. dollars unless otherwise indicated.
"We delivered another solid quarter, continuing to drive year-over-year growth. Our performance in this quarter was driven by organic growth of our core business, Venom Extracts. As we approach the end of our final quarter and the beginning of a period of transformation, our strengthened and experienced leadership team is laser focused on creating shareholder value, delivering sustainable profitable growth, keeping operating costs low, and scaling the Company for optimal global success."
- Jake Cohen , Chief Executive Officer, Hollister
"Hollister's third quarter results demonstrate the strength of our business and commitment to executing against our strategy. With its strong balance sheet, we believe the Company is well positioned and prepared for growth as it continues on its strategic transformation."
- Eula Adams , Chief Financial Officer, Hollister
Third Quarter 2021 Financial Results
Total revenue was $14.5 million , an increase of $5 million or 53% compared to the prior year period.
Gross profit was $3.5 million compared to $1.4 million for the prior year period.
Net income was $0.4 million versus a loss of $0.6 million in the prior year period.
Adjusted EBITDA was $1.2 million compared to a loss of $0.6 million in the prior year period.
Cash and cash equivalents was $7.6 million , a 300% increase as compared to $1.9 million at June 30, 2020 .
Third Quarter 2021 Business Highlights
On July 13 th , 2021, the Company announced it was added as an index constituent in the Solactive US Marijuana Companies Index (the " Index ") as part of the Index's June 2021 quarterly rebalancing and as a result is now a holding in the Horizons US Marijuana Index ETF (NEO: HMUS).
On August 25 th , 2021, the Company announced ' Hollister Brand Campus ' (the " Campus ") a 30-Acre Arizona Brand Campus with planned 700,000 square feet of cultivation area and an existing 28,500-square-foot processing and manufacturing facility.
On August 31 st , 2021, the Company announced two new board members, Mr. Kevin Harrington , an original "Shark" from the NBC hit TV series "Shark Tank" and Mr. Jakob Ripshtein, the former CFO of Diageo North America and President of Aphria Inc.
On October 18 th , 2021, the Company announced a series of operational and strategic updates to create shareholder value, enhance governance, operations and market positioning while preparing the Company for the next phase of its growth, including:
Appointment of:
Jacob Cohen as Chief Executive Officer
Eula Adams as Chief Financial Officer
Chris Lund as Chief Commercial Officer
Jill Karpe as Senior Vice President of Admin and Finance;
Refocused business strategy to develop a "house of brands" focused on cannabis consumer packaged goods;
Initiated rebranding corporate identity and name of the company; and
Reduction of expenses and resource allocation on non-core business activities.
On November 2 nd , 2021, the Company announced it received an order from the Ontario Securities Commission granting Hollister an exemption from certain provisions governing disclosure and other matters applicable to issuers with outstanding "restricted securities".
On November 23 rd , 2021, all matters put forward before the Company's shareholders for consideration and approval, as listed in the management information circular of the Company dated October 18, 2021 (the " Circular "), were approved by the requisite majority of votes cast at the Company's Annual General and Special Shareholder Meeting. This includes the election of all six (6) Board of Director nominees listed in the Circular: Jakob Ripshtein, Jacob Cohen , Eula Adams , Lily Dash , Kevin Harrington , and Brett Mecum .
The Company believes the outlook is strong and has developed a solid strategy supported by strong operational, financial and leadership capabilities. In January 2021 , the state of Arizona enacted sales of adult-use cannabis ahead of industry expectations. The Company recognized a substantial increase in demand for its branded goods and bulk wholesale products, creating a larger volume of sales in the first half of the year as dispensaries and brands readied for inventory for the market change. During Q3 2021 and beyond the Company focused its efforts on improving sales of higher margin products and aligning supply and demand to flow with the seasonality of the Arizona and cannabis markets at large. Management reports that January through November sales are estimated to exceed $64.5 million. Management believes the previously forecasted guidance of $70 million is achievable and driven by sales of finished and bulk products in the company's core market of Arizona . Historically, fourth quarter sales in Arizona improved versus summer months due to local population increases from seasonal residents returning and holiday visitors. The overall Arizona market demand has seen improvements in the categories that the company operates and is expected to continue.
Sales through the end of November are preliminary and are unaudited and subject to change and adjustment when the Company prepares its audited consolidated financial statements for the year ended December 31, 2021 . Accordingly, investors are cautioned not to place undue reliance on the foregoing information. The preliminary results provided in this news release constitute "forward-looking information" within the meaning of applicable Canadian securities laws, are based on several assumptions and are subject to a number of risks and uncertainties. Actual results may differ materially. See "Cautionary Statement Regarding Forward-Looking Information".
The Company will continue optimizing its platform in Arizona through improved same-store sales, loyalty, and expanding its product portfolio and market penetration. The recently announced Campus project is progressing and once production has commenced it is expected to provide the Company with substantially reduced direct material costs, resulting in improved gross margin. The Campus also has ample space to expand production of higher margin finished products.
As previously announced , the Company is moving forward, implementing its "house of brands" cannabis consumer packaged goods strategy which includes manufacturing and distribution of owned and partner branded cannabis products in chosen markets. Additionally, the Company is planning to rationalize its existing brand and product portfolio, dedicating efforts towards new, highly targeted brand partnerships and the acquisition or development of owned brands.
On the corporate development front, the process to rebrand the Company and to align it with its refined strategy has commenced. Campaigns to improve awareness and broaden the shareholder base are being developed.
The Company has placed certain non-core assets including its California operations in a care and maintenance program to reduce expenses and improve overall financial and operational performance.
In addition to operational, financial, governance and strategy improvements, the Company has also been dedicating efforts to enter new markets with its existing brands.
USE OF NON-IFRS FINANCIAL MEASURES
This press release includes certain non-IFRS financial measures. Reconciliations of these non-IFRS financial measures to the most directly comparable financial measure calculated and presented in accordance with IFRS are included below. This information should be considered as supplemental in nature and not as a substitute for, or superior to, any measure of performance prepared in accordance with IFRS. The Company's management team uses adjusted EBITDA to evaluate operating performance and trends and to make planning decisions. The Company's management team believes adjusted EBITDA helps identify underlying trends in the business that could otherwise be masked by the effect of the items that are excluded. Accordingly, the Company believes that adjusted EBITDA provides useful information to investors and others in understanding and evaluating the operating results, enhancing the overall understanding of past performance and future prospects, and allowing for greater transparency with respect to key financial metrics used by management in its financial and operational decision-making.
The table below reconciles net income (loss) and comprehensive income (loss) to Adjusted EBITDA (Loss for the three and nine months ended September 30, 2021 and 2020:
Net income (loss) and comprehensive income (loss)
Add (deduct) impact of:
Finance costs
Foreign exchange gain
Acquisition expense
Gain on sublease
Gain on lease extinguishment
Lease renegotiation costs
Deferred income tax recovery
Foreign currency translation adjustment
Adjusted EBITDA (Loss)
The live audio earnings conference call may be accessed online and by phone using the link: https://www.renmarkfinancial.com/events/third-quarter-2021-results-cse-holl-2021-11-30-160000 . Investors may pre-register for the call by navigating to the same link provided. The conference call will be archived for replay and accessible at https://hollisterbiosciences.co/investors/ .
About Hollister
Hollister is a multi-state company with a portfolio of innovative, high-quality cannabis & hemp branded consumer products and white-labeling manufacturing. The Company's products are sold in 370 dispensaries across Arizona and California . Hollister's wholly-owned brand, Venom Extracts, is a category-leading brand that sold more than 4 million grams in 2020, accounting for up to 30% of category sales in Arizona .
Products from Hollister include HashBone, the brand's premier artisanal hash-infused pre-roll, along with concentrates (shatter, budder, crumble), distillates, solvent-free bubble hash, pre-packaged flower, pre-rolls, tinctures, vape products and full-spectrum high CBD pet tinctures. The Company's wholly-owned California subsidiary Hollister Cannabis Co is the 1st state and locally licensed cannabis company in the city of Hollister, CA , birthplace of the "American Biker".
Website: www.hollisterbiosciences.co
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION:
This news release includes certain "forward-looking information" as defined under applicable Canadian securities legislation, including statements regarding the plans, intentions, beliefs, and current expectations of the Company with respect to future business activities and operating performance. To the extent any forward-looking information in this news release constitutes "financial outlooks" within the meaning of applicable Canadian securities laws, such information is being provided as preliminary financial and operational results and the reader is cautioned that this information may not be appropriate for any other purpose and the reader should not place undue reliance on such financial outlooks. Forward-looking information is often identified by the words "may", "would", "could", "should", "will", "intend", "plan", "anticipate", "believe", "estimate", "expect" or similar expressions and includes information regarding: the impacts of the Campus; the implementation of the Company's " house of brands" cannabis consumer packaged goods strategy; the Company's rebranding; and expectations for other economic, business, and/or competitive factors. Forward-looking information is necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking information. Financial outlooks, as with forward-looking information generally, are, without limitation, based on the assumptions and subject to various risks as set out herein. The Company's actual financial position and results of operations may differ materially from management's current expectations and, as a result, the Company's revenue may differ materially from the estimated revenue provided in this news release.
Investors are cautioned that forward-looking information is not based on historical fact but instead reflects management's expectations, estimates or projections concerning future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although the Company believes that the expectations reflected in such forward-looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance, or achievements of the Company. Among the key factors that could cause actual results to differ materially from those projected in the forward-looking information are the following: the Company's financial results, including the Company's revenue for the year to date will be as projected; regulatory and licensing risks; changes in consumer demand and preferences; changes in general economic, business and political conditions, including changes in the financial markets; the global regulatory landscape and enforcement related to cannabis, including political risks and risks relating to regulatory change; compliance with extensive government regulation; public opinion and perception of the cannabis industry; the impact of COVID-19; and the risk factors set out in the Company's annual information form dated August 28, 2020 , filed with Canadian securities regulators and available on the Company's profile on SEDAR at www.sedar.com .
The Company, through several of its subsidiaries, is indirectly involved in the manufacture, possession, use, sale, and distribution of cannabis in the recreational and medicinal cannabis marketplace in the United States . Local state laws where the Company operates permit such activities however, investors should note that there are significant legal restrictions and regulations that govern the cannabis industry in the United States . Cannabis remains a Schedule I drug under the US Controlled Substances Act, making it illegal under federal law in the United States to, among other things, cultivate, distribute or possess cannabis in the United States . Financial transactions involving proceeds generated by, or intended to promote, cannabis-related business activities in the United States may form the basis for prosecution under applicable United States federal money laundering legislation.
While the approach to enforcement of such laws by the federal government in the United States has trended toward nonenforcement against individuals and businesses that comply with recreational and medicinal cannabis programs in states where such programs are legal, strict compliance with state laws with respect to cannabis will neither absolve the Company of liability under United States federal law, nor will it provide a defense to any federal proceeding which may be brought against the Company. The enforcement of federal laws in the United States is a significant risk to the business of the Company and any proceedings brought against the Company thereunder may adversely affect the Company's operations and financial performance.
Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated, or expected. Although the Company has attempted to identify important risks, uncertainties and factors that could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. Accordingly, readers should not place undue reliance on forward-looking information, which speak only as of the date of this news release. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by law.
View original content to download multimedia: https://www.prnewswire.com/news-releases/hollister-biosciences-announces-third-quarter-fiscal-2021-financial-results-including-revenue-of-usd-14-5m-and-adjusted-ebitda-of-usd-1-2m-301433346.html
SOURCE Hollister Biosciences Inc.
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/November2021/29/c3140.html
Hollister Biosciences CNX:HOLL HSTRF Psychedelics Investing
Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn"), a biotechnology company developing and delivering psychedelic therapeutics (medicines and therapies) to treat addiction, announces that it has been requested by OTC Markets Group Inc. ("OTC Markets") to issue this statement about certain promotional activity concerning its common stock.
On Wednesday, January 12, 2022, OTC Markets informed the Company that it became aware of certain promotional activities concerning the Company and its common stock traded on the OTCQB Marketplace, specifically the distribution of promotional emails on January 12, 2022, by third-parties discussing the growing ketamine revolution, citing the Company's potential growth in the space. Upon review, the Company determined that a third party, which was not engaged by the Company or any of its officers, directors, controlling shareholders or any third-party service providers distributed promotional emails. The Company had no editorial oversight of the promotional material or any opportunity to review in advance of the distribution; however, the Company has subsequently reviewed the specific details related to the Company that were included in such promotional emails, and has confirmed these details to be factual. The Company wishes to caution readers that the statements made in such promotional emails are speculative in nature. For more complete and specific information regarding the Company, its prospects and the risks associated with those prospects, readers should review the Company's public filings on SEDAR, its website and other reliable sources. The Company encourages investors to contact their investment advisors prior to making any investment.
Further, the Company understands this promotional activity may have coincided with increased trading activity in the Company's common shares beginning on or about January 5, 2022. The Company does not believe the promotional activities were a factor in the recent increase in trading volume of the Company's common shares. Instead, the Company attributes the increased trading volume to currently heightened investor interest as a result of its recent press releases which disclosed voluntary lock-up agreement from a number of shareholders, the expansion of its Ketamine for gambling disorder to include several other behavioural addictions, as well as the release of positive results of the phase-II a/b study for Ketamine-assisted therapy for the treatment of Alcohol Use Disorder.
After an inquiry by management, none of the Company's executive officers, directors or, to the knowledge of the Company, any controlling shareholders or third-party service providers sold or purchased shares of common stock of the Company within the past 90 days.
In the last twelve months, the Company has engaged JRZ Capital (as previously disclosed in a press release dated October 8, 2021), KCSA Strategic Communications for investor and public relations services, as well as other news organizations including Investing News Network, Agoracom, InvestorIntel, Just Capital Consulting and The Dales Report.
The OTC Markets has further requested that the Company state whether it has issued any shares or convertible instruments allowing conversion to equity securities at prices constituting a discount to the current market price at the time of the issuance, which the Company has not.
About Awakn Life Sciences Corp.
Awakn Life Sciences is a biotechnology company developing and delivering psychedelic therapeutics (medicines and therapies) to better treat addiction. Awakn's team consists of world leading chemists, scientists, psychiatrists, and psychologists who are developing and advancing the next generation of psychedelic drugs, therapies, and enabling technologies to treat addiction. Awakn will deliver these evidence backed psychedelic therapies in clinics in the UK and Europe and through licensing partnerships globally.
www.awaknlifesciences.com | Twitter | LinkedIn | Facebook
Notice Regarding Forward-Looking Information
This news release contains certain forward-looking information and forward-looking statements, as defined in applicable securities laws (collectively referred to herein as "forward-looking statements"). Forward-looking statements reflect current expectations or beliefs regarding future events or the Company's future performance. All statements other than statements of historical fact are forward-looking statements. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects", "is expected", "budget", "scheduled", "estimates", "continues", "forecasts", "projects", "predicts", "intends", "anticipates", "targets" or "believes", or variations of, or the negatives of, such words and phrases or state that certain actions, events or results "may", "could", "would", "should", "might" or "will" be taken, occur or be achieved, including statements relating to the business of the Company. All forward-looking statements, including those herein are qualified by this cautionary statement.
Although the Company believes that the expectations expressed in such statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the statements. There are certain factors that could cause actual results to differ materially from those in the forward-looking information. These include: the business plans and strategies of the Company, the ability of the Company to comply with all applicable governmental regulations in a highly regulated business; the inherent risks in investing in target companies or projects which have limited or no operating history and are engaged in activities currently considered illegal in some jurisdictions; changes in laws; limited operating history; reliance on management; requirements for additional financing; competition; inconsistent public opinion and perception regarding the medical-use of psychedelic drugs; and regulatory or political change. Readers are cautioned that the foregoing list of factors is not exhaustive of the factors that may affect forward-looking statements. Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking statements in this news release speak only as of the date of this news release or as of the date or dates specified in such statements.
Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking information. For more information on the Company, investors are encouraged to review the Company's public filings on SEDAR at www.sedar.com. The Company disclaims any intention or obligation to update or revise any forward- looking information, whether as a result of new information, future events or otherwise, other than as required by law.
Investor Enquiries:
KCSA Strategic Communications
Valter Pinto / Tim Regan
Awakn@KCSA.com
America and Canada: KCSA Strategic Communications
Anne Donohoe
Adonohoe@KCSA.com
Rest of World: ROAD Communications
Paul Jarman / Anna Ramsey
Awakn@roadcommunications.co.uk
NeonMind Appoints Canadian Medical Leader in Anesthesiology, Dr. Daniel Bainbridge, MD, FRCPC to Its Specialty Clinics Advisory Board
Dr. Bainbridge's Expertise and Network Provides Safety Best-Practices for Administration of Intravenous Ketamine (IV-Ketamine) at NeonMind Clinics
NeonMind Biosciences Inc. (CSE:NEON)(OTCQB:NMDBF)(FRA:6UF) ("NeonMind'' or the "Company"), an integrated drug development and wellness company, announced today the appointment of Dr. Daniel Bainbridge, MD, FRCPC, past President of the Canadian Anesthesiologists Society, Professor from the Department of Anesthesia and Perioperative Medicine at the University of Western Ontario, and Anesthesia Consultant at London Health Sciences Centre, to its Specialty Clinics Advisory Board
NeonMind's medical services division is establishing specialty clinics to enhance access to interventional psychiatry treatments including intravenous ketamine treatment ("IV-ketamine") which has shown promise as a rapid treatment for mood and anxiety disorders and has been included as a recommended treatment into Canadian guidelines by the Canadian Network for Mood and Anxiety Treatments1. Dr. Bainbridge will utilize his substantial experience to ensure NeonMind's protocols, procedures, training, and practices of administering intravenous ketamine are best-in-class and practical from a safety perspective. With over 20 years as a practicing anesthesiologist and his leadership role with the Canadian Anesthesiologists Society, Dr. Bainbridge has vast experience with ketamine and a large network of contacts for NeonMind to train and employ to assure patient safety.
"We are excited to welcome the Canadian leader in anesthesiology, Dr. Bainbridge, to our Specialty Clinics Advisory Board. At NeonMind, we are focused on enhancing access to interventional psychiatry to help address the mental health crisis, including IV-ketamine for mood and anxiety disorders. Safety is of utmost importance for NeonMind's specialty clinics and, with Dr. Bainbridge's involvement in building our programs, we can assure patients and healthcare providers they are receiving best-in-class care for their IV-ketamine administration. He will prove invaluable to enhancing access and wider adoption of NeonMind's IV-ketamine treatment programs," said Robert Tessarolo, President & CEO of NeonMind.
Dr. Bainbridge commented, "The evidence supports that IV-ketamine is safe and well tolerated at the therapeutic doses used to treat patients suffering from mood and anxiety disorders. The ketamine doses used are magnitudes lower than for procedural sedation, let alone general anesthesia. Ketamine administration requires specific procedures and expertise and can be safely provided in specialty clinics with the appropriately trained health care provider. My colleagues at NeonMind understand this with the aim of enhancing access to this transformational treatment for mood and anxiety disorders utilizing safe and effective care programs. I am excited to work with NeonMind in developing IV-ketamine administration practices and establishing a clinic network to enhance access to these treatment programs for patients in need."
1. Swainson, J., McGirr, A., Blier, P., Brietzke, E., Richard-Devantoy, S., Ravindron, N., Blier, J., McIntyre, R., Milev, R., Parikh, S., Schaffer, A., Taylor, V., Tourjman, V., van Ameringen, M., Yatham, L., Ravindran, A. and Lam, R., 2021. The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Recommendations for the Use of Racemic Ketamine in Adults with Major Depressive Disorder. The Canadian Journal of Psychiatry, 66(12), pp.1102-1102.
About NeonMind Biosciences Inc.
NeonMind operates two divisions: (i) a pharmaceutical division engaged in drug development of psychedelic compounds with two lead psilocybin-based drug candidates targeting obesity; and (ii) a medical services division focused on launching specialty mental health clinics that integrate psychedelic therapeutics into traditional psychotherapy settings.
In its pharmaceutical division, NeonMind has two distinct psilocybin drug development programs targeting obesity. NeonMind's lead candidate, NEO-001, employs psilocybin as an agonist at the serotonin 5- HT2A receptor, which is involved in the hallucinogenic effect of psychedelics. The Company's second drug candidate, NEO-002, employs low-dose psilocybin as an agonist at the 5-HT2C receptor, which controls appetite.
NeonMind and its strategic partners are building NeonMind-branded specialty mental health clinics in Canada that incorporate evidence-backed innovative treatments to address a variety of mental health needs. For more information on NeonMind, go to www.NeonMindBiosciences.com.
Rob Tessarolo, President & Chief Executive Officer, NeonMind Biosciences Inc.
rob@neonmind.com
Scott Eckstein/Tim Regan
neonmind@kcsa.com
The Canadian Securities Exchange has not reviewed, approved nor disapproved the contents of this news release.
Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or NeonMind's future performance. The use of any of the words "could", "expect", "believe", "will", "projected", "estimated" and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on NeonMind's current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, NeonMind's drug development plans, its ability to retain key personnel, and its expectation as to the development of its intellectual property and other steps in its preclinical and clinical drug development constitute forward-looking information. Actual results and developments may differ materially from those contemplated by forward-looking information. Readers are cautioned not to place undue reliance on forward-looking information. The statements made in this press release are made as of the date hereof. NeonMind disclaims any intention or obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as may be expressly required by applicable securities laws.
SOURCE: NeonMind Biosciences Inc.
https://www.accesswire.com/683324/NeonMind-Appoints-Canadian-Medical-Leader-in-Anesthesiology-Dr-Daniel-Bainbridge-MD-FRCPC-to-Its-Specialty-Clinics-Advisory-Board
Levitee Labs Signs Retail Distribution Agreement with Body Energy Club for MONKE Nutraceuticals
In business for 20 years, Body Energy Club is the leading health supplement and vitamin retailer in Western Canada, with additional locations established in Hollywood, California in 2017
Levitee Nutraceuticals, a division of Levitee Labs , brand MONKE Nutraceuticals ™ currently has two health supplements, MONKE Mind and MONKE Body with line extensions launching 2022
The premium functional mushroom supplements can retail in up to all 17 Body Energy Club retail locations and on its ecommerce platform, www.BodyEnergyClub.com
Levitee Labs Inc. (CSE: LVT) (OTC: LVTTF) (FSE: 7H7) (the "Company" or "Levitee"), an integrative wellness company with a diversified portfolio of healthcare and wellness assets, is pleased to announce the execution of a distribution agreement (the "Agreement") with Body Energy Club, the leading health supplement and vitamin store in Canada.
Per the Agreement, Body Energy Club will begin offering the Company's MONKE Mind and MONKE Body product line at select brick-and-mortar locations in Vancouver with expansion potential to all 17 retail locations in the Lower Mainland in Canada and Hollywood, California, plus the Body Energy Club ecommerce site . MONKE Mind and MONKE Body are premium, 100% organic functional mushroom supplements specifically formulated for focus, energy, and strength and immunity, vitality, and longevity, respectively.
Founded in 2002 by Dominick Tousignant, Body Energy Club began has grown into a chain of 10 corporate-owned locations and 7 franchises acclaimed for featuring ultra-high-end health and wellness products. Body Energy Club offers its own private label brand in addition to a meticulously selected group of over 200 other brands that fit its model of ensuring that premium healthy lifestyle choices are available and affordable for everyone.
The Agreement further stipulates that MONKE™ products will be part of the Body Energy Club Rebate program. This is an important inclusion, as it leads to franchise locations placing orders for MONKE Mind and MONKE Body products. In the coming days, the Company will be prominently featured through in-store demonstrations and kicking off a new social media campaign meant to create additional exposure. The social media campaign will award prizes for participants following, liking and sharing information and promotions on MONKE products and Body Energy Club.
"Body Energy Club is ' the ' health and wellness retailer frequented by hundreds of loyal customers daily in the Greater Vancouver area. It is a thrill to develop this partnership providing us valuable shelf space in their physical and virtual stores," said Pouya Farmand, Chief Executive Officer at Levitee Labs. "We greatly respect that Body Energy Club is highly selective in the products it stocks, which speaks volumes to the quality of MONKE Nutraceuticals™. We look forward to a long relationship with their certified team of nutrition experts and opportunities for additional placements from the 180+ SKUs in our portfolio."
"As we come out of the other side of the COVID-19 pandemic, health is of utmost importance to consumers today. At Body Energy Club, we are highly focused on curating product lineups that takes some of the work out of it for our customers to understand which products are the best and most effective," said Dominick Tousignant, Founder of Body Energy Club. "The MONKE products of Levitee Labs align perfectly with our mission and commitment to product excellence. I am equally impressed with the Levitee Labs team and their vision to execute marketing strategies that will result in additional foot and virtual traffic."
About Body Energy Club
Body Energy Club is one of Canada's leading and most trusted providers of vitamin and nutritional supplements in Canada. Body Energy Club operates a warehouse facility to support both its brick and mortar stores in the United States and Canada, as well as its online store, which is one of the largest online vitamin and nutritional supplement stores in Canada. Body Energy Club has a range of over 6,200 products with over $4 million in inventory.
About Levitee Labs
Levitee is establishing itself as a leader in the integrative wellness space. Through integrating evidence-based complementary medicines into the traditional infrastructure of mental health and addiction services, Levitee aims to transform mental health and addiction treatments.
The Company's current portfolio of assets includes: Levitee Clinics™, a group of five operating addiction and pain treatment clinics in Alberta; Levitee Pharmacies™, three pharmacies operating in Alberta specialized in filling prescriptions for patients with substance use disorders, mental health conditions, and chronic pain; BlockMD, the first technology company in Alberta to receive provincial approval for electronic-prescriptions in the addiction treatment space; and Earth Circle Organics, a direct-to-consumer and wholesaler of supplements and superfood products with 180+ SKUs in its product lineup across three brands. Further information about Levitee is available on its website at www.leviteelabs.com.
Investor and Corporate Communications:
Pouya Farmand, CEO & Co-Founder
ir@leviteelabs.com
Olivia Belcher-Coward, Marketing & Communications Manager
media@leviteelabs.com
This news release contains certain statements that may constitute forward-looking information under applicable securities laws. All statements, other than those of historical fact, which address activities, events, outcomes, results, developments, performance, or achievements that Levitee anticipates or expects may or will occur in the future (in whole or in part) should be considered forward-looking information. Such information may involve, but is not limited to, statements respecting Levitee's business plans and proposed products, and the benefits derived from mushroom-infused products; the acquisitive growth potential of Levitee once acquisitions are completed; the expectation that Levitee will continue to execute its accretive acquisition program, and the contribution of such program to Levitee's future growth potential; and Levitee's objective to transform mental health and addiction treatments through the integration of psychedelic medicines and therapies. Often, but not always, forward-looking information can be identified by the use of words such as "plans", "expects", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates", or "believes" or variations (including negative variations) of such words and phrases, or statements formed in the future tense or indicating that certain actions, events or results "may", "could", "would", "might" or "will" (or other variations of the forgoing) be taken, occur, be achieved, or come to pass. These statements and other forward-looking information are based on assumptions made by Levitee based on currently available competitive, financial and economic data and operating plans, strategies or beliefs as of the date of this news release as well as management's current expectations or beliefs regarding future growth, results of operations, future capital (including the amount, nature and sources of funding thereof) and expenditures. These assumptions may also be based on information obtained from third-party industry analysts and other third-party sources. Forward-looking information is necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by Levitee as of the date such statements are made, are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, performance or achievements to be materially different from those expressed or implied by such forward-looking information, including but not limited to risks associated with the following: Levitee's limited history of operations; ability to secure additional financing; negative cash flow from operating activities since inception; regulatory requirements; changes in consumer preferences; supply of raw materials; reliance on a limited number of products; brand awareness; the ability to develop, market and produce new products; dependence on certain key senior managers; reliance on third parties for manufacturing and packaging; potential product liability claims and product recalls; and significant competition. For additional information regarding these risks, please see the risk factors identified and reported in Levitee's public filings under its SEDAR profile at www.sedar.com. Any and all forward-looking information contained in this press release is expressly qualified by this cautionary statement. Readers are cautioned not to place undue reliance on forward-looking statements or information. The forward-looking information is made as of the date of this news release, and Levitee assumes no obligation to publicly update or revise such forward-looking information, except as required by applicable securities laws. The CSE (operated by CNSX Markets Inc.) has neither approved nor disapproved of the contents of this press release and accepts no responsibility for the adequacy or accuracy hereof.
Special Access to Psychedelics in Canada a "Huge Plus" for Industry
Canada has approved some psychedelic substances for medical use, kicking off a potentially busy 2022.
Last Wednesday (January 5), the psychedelics industry was encouraged to see changes to Canada's Special Access Program confirmed in the latest edition of the Canada Gazette, the government's official newspaper.
Under special circumstances, patients will now be able to receive psilocybin and MDMA in medical environments.
Government consultation shows united support
In December 2020, the Canadian government asked for a consultation with the public through opinion submissions regarding the use of psychedelic-based medicine.
"Over 80% of all respondents associated Health Canada's proposal with increasing access to psychedelic restricted drugs," the Canada Gazette states.
The government has been very clear in signaling that this change does not mean these substances will not now become available on a wide scale similar to cannabis.
The amendments allow Health Canada to authorize the sale of restricted drugs for its Special Access Program, which according to the government is exclusively for emergency treatment patients.
"All requests will continue to be assessed on a case-by-case basis, taking into consideration the level of evidence regarding the safety and efficacy for the proposed use, as well as the patient's condition and their clinical status," the government's statement explains.
Psychedelics industry reacts to change in rules
According to one psychedelics company, the regulatory change in Canada was driven by the amount of research showing the medical benefits of psychedelic substances.
"While we believe this is only the beginning of greater change to come, it signifies an important step towards creating expanded safe access to treatment and care in the mental health sector through psychedelic medicine," Payton Nyquvest, founder and CEO of Numinus Wellness (TSX:NUMI), said in a statement to shareholders.
Bill Fleming, president and CEO of Halucenex, a subsidiary of Australian cannabis company Creso Pharma (ASX:CPH,OTCQB:COPHF), told the Investing News Network (INN) that this change is a gigantic win for patients.
Fleming added that moves like this open the doors for the established medical community to gain a better understanding of psychedelic medicine. Additionally, this new stance on regulations will boost medical research.
"This is a huge plus for Canadian companies and the psychedelic industry in general," Fleming told INN. "We'll see maybe more of that medical environment opening up in a bigger (and) better way over the next year or two."
Clinical studies could be boosted by special access
There's been a rush of studies and clinical trials investigating how psychedelic compounds and medicines can be used to treat patients, and that trend is not slowing down in 2022.
Sabrina Ramkellawan, co-founder and chief operating officer of the Knowde Group, as well as research committee lead with MAPS Canada, previously told INN she is working diligently with clients across the board on fine tuning all types of clinical trials for psychedelic drugs.
Fleming agreed with Ramkellawan, saying he expects to see a significant uptick in clinical data over the next 12 to 18 months, and it should meaningfully change the acceptance of these drugs.
When asked about the reaction to the news from the public, Fleming told INN it will take time for the market to really grasp and absorb this regulation change in Canada.
He said the ruling will show skeptical investors who haven't jumped into the psychedelics space that they can feel more comfortable. Fleming added, "More importantly, it also says that now is the time for the market to look at (the industry) and say, 'Where do we go next?'"
Don't forget to follow @INN_LifeScience for real-time updates!
Editorial Disclosure: Numinus Wellness is a client of the Investing News Network. This article is not paid-for content.
The Investing News Network does not guarantee the accuracy or thoroughness of the information reported in the interviews it conducts. The opinions expressed in these interviews do not reflect the opinions of the Investing News Network and do not constitute investment advice. All readers are encouraged to perform their own due diligence.
Awakn Life Sciences Announces Positive Results from Phase II A/B Ketamine-Assisted Therapy for Treatment of Alcohol Use Disorder Trial
Primary and Secondary Endpoints Achieved, Including 86% Abstinence Over 6 Months Post Treatment and No Serious Adverse Events
Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a biotechnology company developing and delivering psychedelic therapeutics (medicines and therapies) to treat addiction, is delighted to announce ground-breaking positive data from their Phase II AB trial. It was the first controlled trial in the world to investigate Ketamine-Assisted Therapy for the treatment of Alcohol Use Disorder (AUD), the results have been published in the American Journal of Psychiatry. The trial was conducted by University of Exeter (UoE) and led by Professor Celia Morgan, Awakn's Head of Ketamine-Assisted Therapy for Addiction and Professor of Psychopharmacology at UoE. Awakn acquired the intellectual property (IP) to the therapy under license for use in further research, its clinics in Europe, and its partnerships globally.
The positive Phase II trial outcome and Awakn's newly formed partnership with the UK National Healthcare Service (NHS) and UoE, paved the way to progress this trial into Phase III. With the ultimate aim of securing regulatory approval for Ketamine-Assisted Therapy to treat AUD in the UK through the NHS and potentially in other territories.
The double-blind placebo-controlled trial included 96 patients with severe AUD, who were randomised to one of four groups: 1) three ketamine infusions (0.8 mg/kg IV over 40 minutes) plus proprietary manualized therapy (KARE); 2) three saline infusions plus KARE therapy; 3) three ketamine infusions plus alcohol education; and 4) three saline infusions plus alcohol education.
The primary outcomes of the trial were 1) Days abstinent in the 6 months after treatment, 2) Relapse at 6 month follow up. The findings showed that ketamine combined with KARE therapy, resulted in total abstinence in 162 of 180 days in the following 6-month period, achieving an increase in abstinence from around 2% prior to the trial to 86% post trial. The results for relapse at 6 months, showed that the Ketamine plus KARE group's risk of relapse, was 2.7 times less than the placebo plus alcohol education group.
"Alcohol Use Disorder is a pervasive and persistent public health issue, affecting at least 390 million people globally. Treatment rates are low and relapse rates post treatment tend to be high. We urgently need new and more effective treatments," said Prof. Morgan. "We found that controlled, low doses of ketamine combined with manualized psychological therapy can significantly increase post treatment abstinence rates. This is extremely encouraging, as we normally see three out of four people returning to heavy drinking within twelve months of treatment. The data we've collected from this study paves the way for a paradigm shift in how AUD is treated."
The secondary outcomes of the study identified further encouraging results including improved liver function across several different markers, a statistically significant decrease in depression after 3 months and an increase in the ability to experience pleasure.
In addition to the primary and secondary endpoints, Prof. Morgan identified further significant results in the reduction in heavy drinking days. At six months post trial, there was an average of 12 heavy drinking days in the Ketamine plus KARE group, this is a large reduction compared to other trials in this area and it is widely believed the real-world data is far higher than this. Within the KARE group there was also a significant decrease in the risk of mortality, 1 in 8 patients would have died within 12 months without treatment, that number decreased to 1 in 80 following the treatment.
In total, the trial demonstrated that three subanesthetic infusions of ketamine support abstinence from alcohol and that abstinence may be further enhanced when ketamine treatment is combined with therapy. No serious adverse events took place during the trial.
Anthony Tennyson, Awakn's Chief Executive, added, "We are so pleased to see such encouraging results in an area of treatment that has been stagnant for so long, leaving so many people with little or sub-par options available to them. We will continue to support this research and future clinical trials as we push to bring a radical shift in the alcohol addiction treatment industry."
See following link for presentation of KARE results - Awakn Life Sciences - KARE Presentation.
Awakn will hold a conference call to go through the results in further detail.
Toll-free Dial-in Number: 1-877-407-0789
International Dial-in Number: 1-201-689-8562
Participant Link: https://viavid.webcasts.com/starthere.jsp?ei=1518205&tp_key=b24ddb9685.
A telephone replay will be available through Wednesday January 26, 2022. To access the replay, please dial 1-844-512-2921 (domestic) or 1-412-317-6671 (international). At the system prompt, please enter the code 13725796 followed by the # sign. You will then be prompted for your name, company, and phone number. Playback will then automatically begin.
This news release contains certain forward-looking information and forward-looking statements, as defined in applicable securities laws (collectively referred to herein as "forward-looking statements"). Forward-looking statements reflect current expectations or beliefs regarding future events or the Company's future performance. All statements other than statements of historical fact are forward-looking statements. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects", "is expected", "budget", "scheduled", "estimates", "continues", "forecasts", "projects", "predicts", "intends", "anticipates", "targets" or "believes", or variations of, or the negatives of, such words and phrases or state that certain actions, events or results "may", "could", "would", "should", "might" or "will" be taken, occur or be achieved, including statements relating to the proposed NEO listing, and the business of the Company. All forward-looking statements, including those herein are qualified by this cautionary statement.
Although the Company believes that the expectations expressed in such statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the statements. There are certain factors that could cause actual results to differ materially from those in the forward-looking information. These include: whether conditions to the listing on NEO will be satisfied; the business plans and strategies of the Company, the ability of the Company to comply with all applicable governmental regulations in a highly regulated business; the inherent risks in investing in target companies or projects which have limited or no operating history and are engaged in activities currently considered illegal in some jurisdictions; changes in laws; limited operating history; reliance on management; requirements for additional financing; competition; inconsistent public opinion and perception regarding the medical-use of psychedelic drugs; and regulatory or political change. Readers are cautioned that the foregoing list of factors is not exhaustive of the factors that may affect forward-looking statements. Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking statements in this news release speak only as of the date of this news release or as of the date or dates specified in such statements.
Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking information. For more information on the Company, investors are encouraged to review the Company's public filings on SEDAR at www.sedar.com. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law.
This news release does not constitute an offer to sell, or a solicitation of an offer to buy, any securities in the United States. The Company's and Awakn's securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.
Levitee Labs Partners with Canntab Therapeutics to Provide Alternatives to Opioids
The agreement is anticipated to contribute to correcting the opioid crisis in Canada and serve as a foundation for both companies to potentially expand into new verticals in the future
Levitee Labs and Canntab Therapeutics have executed a services agreement resulting in Levitee Labs informing patients about the Canntab portfolio of therapeutics
Levitee Labs will offer the entire Canntab product lineup throughout all its clinics and pharmacies in Western Canada
Levitee Labs Inc. (CSE: LVT) (OTC: LVTTF) (FSE: 7H7) (the "Company" or "Levitee"), an integrative wellness company with a diversified portfolio of healthcare and wellness assets, is pleased to announce that the Company has entered into a strategic partnership via a services agreement (the "Agreement") with Canntab Therapeutics Limited (CSE: PILL.CN) (OTCQB: CTABF) (FRA: TBF1.F) ("Canntab"), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications available in multiple doses and timed-release combinations.
Pursuant to the Agreement, Levitee will, where applicable, inform customers throughout its ecosystem of specialized clinics and pharmacies in Alberta and British Columbia about Canntab products as alternative solutions for pain management, addiction, and other disorders. Levitee currently owns five addiction clinics and three specialized pharmacies which have conducted more than 35,000 patient visits in the last 12 months. The partnership is anticipated to enhance patient care and drive additional revenue.
"We share a vision with Canntab to play a meaningful role in flattening the curve of the opioid crisis in Canada by tapering use of addictive painkillers through the substitution of viable alternatives, which can include cannabinoids like CBD and THC and combination thereof," said Noha ElSayed, B.Sc.Pharm, APA, Executive Director, Levitee Clinics and Levitee Pharmacies, Alberta Region. "Notwithstanding the lack of clinical trials for product specific uses, cannabinoids have shown great promise to provide patients relief for multiple indications in which we specialize. I am eager for Canntab to begin servicing our pharmacies and clinics throughout Canada, as it will both drive additional revenue and better serve our patients."
"I see this as the start of what can be a long and prosperous relationship between Canntab and Levitee Labs," added Richard Goldstein, Co-Founder and Chief Financial Officer of CannTab. "Our hard pill formulations are superior to all other medical CBD and THC delivery systems and designed to produce both immediate and durable relief for acute and chronic pain. Furthermore, our manufacturing capacities are not limited. In the future, I see the potential for our production expertise to be extremely synergistic with Levitee's compounding capabilities to provide a diverse portfolio of therapeutics, including those in the psychedelics space when regulations allow."
About Canntab Therapeutics Limited
Canntab is a Canadian phytopharmaceutical company focused on the manufacturing and distribution of a suite of hard pill cannabinoid formulations in multiple doses and timed-release combinations. Long referred to as Cannabis 3.0 by the Company, Canntab's proprietary hard pill cannabinoid formulations provide doctors, patients and consumers with medical grade solutions which incorporate all the features one would expect from any prescription or over the counter medication sold in pharmacies around the world. These will include the following formulations: once a day and extended release, both providing an accurate dose and improved shelf stability.
Canntab holds a Cannabis Standard Processing & Sales for Medical Purposes License, a Cannabis Research License, and an Industrial Hemp License from Health Canada. Canntab trades on the Canadian Securities Exchange under the symbol PILL, on the OTCQB under the symbol CTABF, and on the Frankfurt Stock Exchange under the symbol TBF1.
Levitee is establishing itself as a leader in the integrative wellness space. Through leveraging an M&A regimen that focuses on the centralization of complementary integrative wellness assets, Levitee aims to transform mental health and addiction treatments through the integration of psychedelic medicines and therapies.
The Company's current portfolio of assets includes: Levitee Clinics™, a group of five operating addiction and pain treatment clinics in Alberta; Levitee Pharmacies™, three pharmacies operating in Alberta specialized in filling prescriptions for patients with substance use disorders, mental health conditions, and chronic pain; BlockMD, the first technology company in Alberta to receive provincial approval for electronic-prescriptions in the addiction treatment space; and Earth Circle Organics, a direct-to-consumer and wholesaler of supplements and superfood products with 180+ SKUs in its product lineup across three brands. Further information about Levitee is available on its website at www.leviteelabs.com .
Lion Copper and Gold Corp. Announces Positive Updated Mineral Resource Estimate for its Flagship MacArthur Copper Project


This page lists all the available downloads for Vagrant.
31   config.vm.network "forwarded_port", guest: 3000, host: 3000, host_ip: "127.0.0.1"
34   # using a specific IP.
35   config.vm.network "private_network", ip: "192.168.33.10"
alias gbr="git branch -r "
alias gbg="git branch |grep "
alias gbrg="git branch -r |gpep "
alias gcow="git checkout working "
alias gcod="git checkout development "
alias gcom="git checkout master "
alias gds="git diff --staged "
alias gpush="git push origin HEAD "
alias gpull="git pull origin HEAD "
alias gfpu="git push -f "
Copyright © 2017 28歳からはじめるフリーランスLIFE! All Rights Reserved.


This eye-catching ring features organic shapes of inlaid turquoise with genuine branch coral, an entirely inlaid turquoise band, and a hollow center that creates interest and depth! Made by hand in Nepal. 1.5" diameter circle. Size 8 1/2.


text:
In the Kuban made a test run of a new plant for the production of aerated concrete
11.09.2012 Category: UkraineAuthor: admin
Ltd. "Glavstroy Labinsk" has made a test run of the new materials production of aerated autoclaved in Labinsk Krasnodar region. Enter the plant in operation the company plans by the end of 2011, the volume of investments is estimated at 1.5 billion rubles. The current level of readiness of the object is 90%. With the release of its full capacity the plant will produce up to 420 thousand cubic meters per year, most of which — building blocks of aerated concrete. The new facility will create 129 new jobs for residents of the municipality, with annual revenues in the budgets of all levels projected at 21 million rubles.
All news 0
Eternal and current
In the north of Israel, in the eastern part of the Jezreel Valley in
Mogilev people Denmark policemen took passports
Two and a half hours the police found out why foreigners visit the graves.
Disasters 0
Noctilucent clouds over Moscow skyscrapers
Moscow, June 8, 2013 © Sergey LisakovClick on the image to view the full
What if the hair fall out?
Hair loss can be a symptom of many diseases, both local and systemic. To
YOU WIN RESPECT, LOVE AND SAVE OUR HISTORY — JOIN U.S.!
Do not allow to FEED "Echo of Moscow" MAY 9 We call on
BaselCement started building 500-hopper cement
Jointly with the machinery sector "Basic Element" Holding began construction of 500 new hopper-cement

redpajama_set_name: RedPajamaCommonCrawl


how to get mystic card album and wot's in them?
and wot cards can i get from them?
Edited by VModCinnamon, 11 May 2018 - 03:31 AM.
Mod Edit: Removed. Do not use red/bold, for mod warnings and notices only.
Wait, what? How much is elvira nowadays?
Tables in bottom of the page. I'm not sure if those rates are right though.
Edited by AJICO, 26 May 2018 - 02:11 AM.
they really should update OBB, OPB, OCA, MCA and so on..


This is an old machine that has just been shipped. On startup everything looks normal and then I get "Keyboard Error 0211" and the PC hangs. I have tried different keyboards and rebooted many times, what could be wrong?
It could be that the connector on your motherboard has been damaged, this may have occured when the system was packed up for shipping. You could try getting a USB keyboard - assuming this PC has a USB connection.
Does the keyboard work in the bios screen?
You could try resetting the bios back to default settings by either taking out the bios battery for a few minutes or using the header on your motherboard (if it has one), but if it still doesn't work in the bios screen and you've tried other keyboards that are known to be OK, then there's got to be something wrong with the motherboard, I'd have thought that by connecting a USB keyboard would have confirmed this.
Go into your BIOS and check for the *halt on* settings - turn the keyboard to not halt on error, save, and reboot - what now?


text:
Schubert Dip
BBC In Concert (30th January 1991)
The Remixes
The Best Of EMF - Epsom Mad Funkers
The Boys from Syracuse [1963 Off-Broadway...
Vernon Duke
We Are Having a Party
MTV Rocks: Indie Revolution
Drew's Famous Best Songs Of The 90's
The Hit Crew(1)
Coyote Ugly
About EMF
When the Madchester craze was at full throttle in the late 1980s/early 1990s, many credible and innovative bands such as the Stone Roses and Happy Mondays were called revolutionaries for fusing Britain's dance culture with their indie rock world. If you subscribe to the notion that art is either revolutionary or plagiarized, EMF may fit into the latter category -- not that they weren't a lot of fun. The band's 1991 smash hit "Unbelievable" introduced unknowing Americans to early Brit Pop by injecting into rock songs a host of dancefloor-friendly beats, looped samples, car sirens and trendy DJ scratching. Eric Shea
C + C Music Factory, Flowered Up, Jesus Jones, The Soup Dragons
Alt Dance
When the Madchester craze was at full throttle in the late 1980s/early 1990s, many credible and innovative bands such as the Stone Roses and Happy Mondays were called revolutionaries for fusing Britain's dance culture with their indie rock world. If you subscribe to the notion that art is either revolutionary or plagiarized, EMF may fit into the latter category -- not that they weren't a lot of fun. The band's 1991 smash hit "Unbelievable" introduced unknowing Americans to early Brit Pop by injecting into rock songs a host of dancefloor-friendly beats, looped samples, car sirens and trendy DJ scratching.
Eric Shea
Brit Pop/Brit Rock
Woo!!!
Football Anthems 2016
Spit'n Rebel Music (feat. Edap & Malc Fresh)
Pop Decades: 90s
Kiss Me, Kate [1959 Capitol Studio Cast]


text:
// SAX error handler.
// http://www.saxproject.org
// No warranty; no copyright -- use this as you will.
// $Id: ErrorHandler.java,v 1.10 2004/03/08 13:01:00 dmegginson Exp $

namespace Sax
{
    ///
    /// Basic interface for SAX error handlers.
    ///
    /// <remarks>
    /// This module, both source code and documentation, is in the
    /// Public Domain, and comes with NO WARRANTY.
    /// Seehttp://www.saxproject.org
    /// for further information.
    /// <para/>
    /// If a SAX application needs to implement customized error
    /// handling, it must implement this interface and then register an
    /// instance with the XML reader using the
    /// <see cref="IXMLReader.ErrorHandler"/>
    /// property. The parser will then report all errors and warnings
    /// through this interface.
    /// <para/>
    /// WARNING: If an application does not
    /// register an ErrorHandler, XML parsing errors will go unreported,
    /// except that SAXParseExceptions will be thrown for fatal errors.
    /// In order to detect validity errors, an ErrorHandler that does something
    /// with <see cref="Error(SAXParseException)"/> calls must be registered.
    /// <para/>
    /// For XML processing errors, a SAX driver must use this interface
    /// in preference to throwing an exception: it is up to the application
    /// to decide whether to throw an exception for different types of
    /// errors and warnings.Note, however, that there is no requirement that
    /// the parser continue to report additional errors after a call to
    /// <see cref="FatalError(SAXParseException)"/>.  In other words, a SAX driver class
    /// may throw an exception after reporting any fatalError.
    /// Also parsers may throw appropriate exceptions for non - XML errors.
    /// For example, <see cref="IXMLReader.Parse(InputSource)"/> would throw
    /// an <see cref="System.IO.IOException"/> for errors accessing entities or the document.
    /// </remarks>
    /// <since>SAX 1.0</since>
    /// <author>David Megginson</author>
    /// <version>2.0.1+ (sax2r3pre1)</version>
    /// <seealso cref="IXMLReader.ErrorHandler"/>
    /// <seealso cref="SAXParseException"/>
    public interface IErrorHandler
    {
        ///
        /// Receive notification of a warning.
        ///
        /// <remarks>
        /// SAX parsers will use this method to report conditions that
        /// are not errors or fatal errors as defined by the XML
        /// recommendation.The default behaviour is to take no
        /// action.
        /// <para/>
        /// The SAX parser must continue to provide normal parsing events
        /// after invoking this method: it should still be possible for the
        /// application to process the document through to the end.
        /// <para/>
        /// Filters may use this method to report other, non-XML warnings
        /// as well.
        /// </remarks>
        /// <param name="exception">The warning information encapsulated in a SAX parse exception.</param>
        /// <exception cref="SAXException">Any SAX exception, possibly wrapping another exception.</exception>
        /// <seealso cref="SAXParseException"/>
        void Warning(SAXParseException exception);

        ///
        /// Receive notification of a recoverable error.
        ///
        /// <remarks>
        /// This corresponds to the definition of "error" in section 1.2
        /// of the W3C XML 1.0 Recommendation.For example, a validating
        /// parser would use this callback to report the violation of a
        /// validity constraint.The default behaviour is to take no
        /// action.
        /// <para/>
        /// The SAX parser must continue to provide normal parsing
        /// events after invoking this method: it should still be possible
        /// for the application to process the document through to the end.
        /// If the application cannot do so, then the parser should report
        /// a fatal error even if the XML recommendation does not require
        /// it to do so.
        /// <para/>
        /// Filters may use this method to report other, non-XML errors
        /// as well.
        /// </remarks>
        /// <param name="exception">The error information encapsulated in a SAX parse exception.</param>
        /// <exception cref="SAXException">Any SAX exception, possibly wrapping another exception.</exception>
        /// <seealso cref="SAXParseException"/>
        void Error(SAXParseException exception);

        ///
        /// Receive notification of a non-recoverable error.
        ///
        /// <remarks>
        /// There is an apparent contradiction between the
        /// documentation for this method and the documentation for
        /// <see cref="IContentHandler.EndDocument()"/>.  Until this ambiguity
        /// is resolved in a future major release, clients should make no
        /// assumptions about whether EndDocument() will or will not be
        /// invoked when the parser has reported a FatalError() or thrown
        /// an exception.
        /// <para/>
        /// This corresponds to the definition of "fatal error" in
        /// section 1.2 of the W3C XML 1.0 Recommendation.For example, a
        /// parser would use this callback to report the violation of a
        /// well-formedness constraint.
        /// <para/>
        /// The application must assume that the document is unusable
        /// after the parser has invoked this method, and should continue
        /// (if at all) only for the sake of collecting additional error
        /// messages: in fact, SAX parsers are free to stop reporting any
        /// other events once this method has been invoked.
        /// </remarks>
        /// <param name="exception">The error information encapsulated in a SAX parse exception.</param>
        /// <exception cref="SAXException">Any SAX exception, possibly wrapping another exception.</exception>
        /// <seealso cref="SAXParseException"/>
        void FatalError(SAXParseException exception);
    }
}

redpajama_set_name: RedPajamaGithub


Please Note: When there is a Funeral Mass in the parish, there will not be any 9:30 am Mass in either Ruan or Dysart.
Next Baptism Course: Ruan on Saturday 13th August from 11:00 am to 12 Noon.
All people intending to have children baptised must complete the baptismal course before each child is baptised.
New Bishop Appointed: Fr Fintan Monahan for the Tuam Diocese has been appointed Bishop of Killaloe and we welcome him to the Diocese.
Recent Baptisms: We welcome into our Community Ewan James Courtney, son of Aidan and Valerie who was baptised recently.
No Exercise Classes: There are no Fitness 4 Fun Classes with John Conroy in Ruan Community Centre on Wednesday 10th August.
Tea/Coffee Morning continues every Tuesday Morning in Ruan Community Centre at 10:00 am. All are welcome.
Samaritans Ennis & Clare branch gratefully acknowledge €142.20 collected in Dysart and €141.18 collected in Ruan at the recent church gate collections. All the work that we do at Samaritans is carried out by volunteers who give their time to provide confidential emotional support to callers. We rely entirely on voluntary donations to finance the operation of the branch so that we can reach out to people who need such support. We are very grateful for this generous donation from the people of Dysart and Ruan. It will be put to good use in helping us to provide the 24 Hour a Day/ Seven Days a week service that is vital to so many people, particularly during these difficult times.
Music Ministry Together is hosting concert of Liam Lawton on Friday 19th August at 8pm in Cistercian College Roscrea. Tickets are €15 and are available from the Guesthouse, Mt St Joseph (0505) 25600 or atwww.eventbrite.ie. Music Ministry Together is a summer school for those who sing and play in their parishes. Musicians and Singers alike: Come Participate in Music Ministry Together (MMT) from 16th - 21st August. Please contactwww.musicministry.ie for further details.
Ruan Hurling/Camogie club are hosting camp for all primary school players commencing 23rd August 2016. In order to continue this camp going forward the clubs have agreed to hold a fundraising dance in Purcells Bar with Break Free Band kindly sponsored by Kieran and Loretta on 27th August 2016. Tickets €5 - are on sale. The Club appreciates and welcomes the continued support from the Parish to our Clubs activities.
Five lucky dips: Carmel O'Halloran, Eileen Brennan, Emer O'Halloran, Teagan Foudy and Michael Lyons.


Aspire Teaching School Alliance is committed to the recruitment and retention of high quality teachers in order to meet the needs of our locality. We have a strong partnership of schools in North Hampshire and our diverse alliance of schools has been involved in delivering high quality teacher-training for many years. We are now able to offer a route into teaching through our School Direct Programme which will begin in September 2018. The application process begins in October 2017 through UCAS.


text:
Disclosure not enough
By Corruption Watch 03 Dec 2012, 12:01
Are you witnessing corruption but don't know what to do about it? Ask the team of Corruption Watch experts what to do by writing to: letters@businesstimes.co.za and mark your letter 'Dear Corruption Watch'.
Dear CW,
I see that the Public Service Commission (PSC) has reported recently that corruption in the public service costs us almost R1 billion! The commission's DG is quoted in the press as saying that the fundamental problem is senior managers in the public service who also have business interests and get away with this simply by disclosing such interests. How do we put an end to this?
Disclosure-ain't-enough
Dear Disclosure-ain't-enough,
No, disclosure is not enough. We have been consistent in saying strongly that under no circumstances should public servants be permitted to own a company providing goods or services to the department in which they are employed.
Public servants must pay heed to the laws, regulations and guidelines that govern their conditions for employment. And these codes of conduct must be enforced with prosecutions and suitable punishment for violations.
• The regulations to the Municipal Finance Management Act prohibit persons in the service of the state at local government level from bidding for government contracts;
• The Prevention and Combating of Corrupt Activities Act makes it an offence, subject to certain exceptions, for a public official to hold a private interest in any contract connected to the public body that employs the official;
• The Code of Conduct for Public Servants and the Explanatory Manual on the Code of Conduct prohibits employees from undertaking outside remunerative work without prior approval;
• The Public Service Act states that employees should not perform work outside their employment except with the written permission of the executive authority of the department;
• The Regulations to the Public Finance Management Act (PFMA) requires supply chain management officials and other role players to recognise and disclose any conflict of interest that may arise.
How do we make disclosure a better bulwark against corruption creep? How do we curb the abuse of position in the public service? To stop such activity we must ensure that the consequences outweigh the benefits and make the business of corruption shameful.
The Financial Disclosure Framework, set up to provide a check on corruption, requires disclosure on shares and other financial interests, directorships and partnerships, remunerated work outside of the public service, consultancies and retainerships, sponsorships, gifts and hospitality from a source other than a family member, and land and property (both inside and outside the Republic). A commissioner of oaths certifies the information.
Now this is a pretty comprehensive disclosure required from a public servant, and yet too few are held to account.
There must be a "cost benefit analyisis" going on in the mind of the corrupt official. "If I get caught is it likely to be a slap on the wrist, 'redeployment', or prosecution and punishment?" We want public officials to think far more carefully about putting their hands in the till because the personal risk becomes too high.
Corruption Watch is in possession of a document detailing – in the Eastern Cape health department alone – that 8, 034 employees are directors of active companies, while 929 are listed as suppliers to government departments. Over four years, 35 companies whose directors are spouses of the department's employees rendered services.
It would seem that despite all the legal safeguards put in place, conflict of interest continues unhindered, leading to public servants lining their pockets, with little or no consequences for both conflicted employees and non-compliant accounting officers.
The recent report of the PSC clearly establishes that these constitute gross conflicts of interest and are a major source of corruption and recommends their outright prohibition. Their recommendations should be made law.
Take a stand and report an incident of corruption. This article originally appeared in the Sunday Times Business Times on 2 December 2012.
I see that the Public Service Commission has reported recently that corruption in the public service costs us almost R1 billion! The DG is quoted in the press as saying that the fundamental problem is senior managers in the public service who also have business interests and get away with this simply by disclosing such interests. How do we put an end to this?
High-flying Joemat-Pettersson gets a big 0
Youngsters urged to speak out for a cleaner SA!


Yellow seems to be a common theme in the world of London-based folk duo Ferris and Sylvester. Following their debut EP, The Yellow Line, Issy Ferris and Archie Sylvester have released the single "Better in Yellow", off their upcoming EP, Made in Streatham.
Filmed in 80's-esque 4:3, the video for "Better in Yellow" is full of visually appealing shots with a sunshine yellow theme and old-timey TV feel. The simplicity of the visuals allows for a spotlight on the lyrics and instrumentation of the track. A tribute to standing out instead of letting one's originality be sucked up by the humdrum of the world, "Better in Yellow" is sure to flood your day with hope and happiness. There's something so heart-warming about watching someone get an egg cracked on their head, covered in yellow paint, and rained upon with potato chips.
With a unique sound combining folky tunes with hints of blues, and even a touch of trumpet, "Better in Yellow" is not to be missed. Ferris and Sylvester know how to not only work together on a musical level, but also in matters of aesthetic, and the "Better in Yellow" video is tribute to this.


It's time to go beyond the ordinary pink and blue and create a whole new bedroom experience for the kids. Update the decor, furniture, and structural architecture to indulge their sense of adventure and fuel their imaginations. You'll soon find you have the happiest kings and queens, pirates, astronauts, and explorers for children. So what does it take to think outside of the box? Perhaps the promise of loot and gold might serve as inspiration.
The perfect room can't have a less-than-perfect bed. It completes the picture by adding a real-life sense of adventure. Don't skimp on details either since the bed is often the focal point of the bedroom. With the ocean for a room and a sunken ship for a bed, you might never have the problem of little children sneaking into your bed again. With that said, we think we just heard you get on board.
Princess or not, there is nothing better to a kid than to have a secret all their own that they can choose to expose. In a themed room, take the initiative to create a hidden passageway, an unseen door, or a secret closet.
Having this all to themselves will help them feel independent, special, and all grown-up.
A mural is the next best thing to achieving the most awesome themed kids' room. Don't be afraid to cover every inch, nook, and cranny to fuel your kid's sense of adventure. The mural should express their unique interests and individuality in a space that's all their own.
If you've got the space, define specific and designated areas for the kids. The separate log cabins in this themed room clearly allows for the kids to claim their own territory which can help reduce squabbling. You know the kind, the "It's not my mess", "That's her stuff" type.
Whoever said only kids enjoy themed rooms?
There's no doubt that kids' rooms are much more fun than grown-ups' rooms. It wouldn't be surprising if you found yourself bunking under the stars or on the ocean floor in your child's room. Adults could learn a thing or two from children who can master living everyday as an adventure. So don't squash their dreams — instead encourage it by making their own living space a reflection of the world they take pleasure in.
If you need inspiration for your child's room take a look at Modernize.com!


Part 4 of my series of posts about Git for .NET deals with merge conflicts, and describes how to resolve them using the command line, Visual Studio and SmartGit. Both Visual Studio and SmartGit offer built in conflict resolution tools. However, it's also possible to solve conflicts with specialist third party conflict resolution tools.
A few months ago, the people at SemanticMerge were kind enough to give me a licence so I could try out the product and cover it in this series. As the name suggests, SemanticMerge is a 'language aware' merge and diff tool. It seeks to limit the amount of conflicts you have to deal with manually, by understanding how to deal with many changes that would typically cause a conflict. It also provides some really nice visualisations of differences between file versions.
This blog describes using SemanticMerge to resolve Git merge conflicts arising in .NET projects. I describe how to integrate SemanticMerge with Git client SmartGit and Visual Studio, and then how to use the tool to resolve merge conflicts. Much of the content will also apply to merge conflicts for other source control systems and languages.
Git merge conflicts are usually triggered by changes to the same text block in a file. Where the system carrying out the merge treats each file as a set of arbitrary blocks of text, it will have difficulty in determining when the changes within a file can be safely combined, and when human intervention is required.
If on the other hand a tool understands the structure of the language involved, it has a better chance of recognising when two changes are compatible. SemanticMerge is able to parse C# files and carry out merges with an understanding of their structure. During the parsing phase, it recognises semantic elements within a file such as methods, properties and classes. A comparison is carried out between these structural elements, rather than text blocks.
A file is modified in one branch and reformatted in the other (for example, a ReSharper code cleanup).
In cases where manual intervention is required (for example, both branches made changes inside a method), SemanticMerge provides a summary of the type of changes that have caused the conflict, and the element involved, so you can understand quickly what you need to resolve.
SemanticMerge and JetBrains have produced a webinar which describes some of the cases SemanticMerge can deal with in more detail.
dst – the destination version of the file. In other words, the version of the file in the branch which is having the other branch's changes merged into it.
SemanticMerge can be used with other source control systems that support three way merging, such as TFS, Mercurial and Plastic SCM.
I'll describe using SemanticMerge to view changes and resolve conflicts later in this blog, after we've got it set up with our Git clients.
Select Conflict Solvers in the Preferences window.
In the Conflict Solvers window, select Add to add a new solver. This opens the Add conflict solver window.
If you want to restrict SemanticMerge to just C# files, you can specify this in the File Pattern area.
In the Command field, enter the location of the SemanticMerge exe on your system.
The Arguments field is where the nuts & bolts of the integration happen. Here, you specify the arguments passed to SemanticMerge when it is triggered by SmartGit. To the right of the field is a drop down menu that you can use to enter 'left file', 'right file' etc in the required format.
This is based on the instructions in on SemanticMerge's guide to Generic Tool Configuration although it took some head scratching to work out what SmartGit's 'left file' and 'right file' corresponded to!
The final step of the integration is to make sure that SemanticMerge is at the top of the list of SmartGit's conflict solvers in SmartGit, by moving it up if necessary.
When you use TFS for source control, third party merge tools can be added through Tools > Options > Source Control > Configure User Tools. However, I can't find a way of directly associating a third party merge tool with Visual Studio when you're using the Git source control plugin.
However! The way round this is to configure Git itself to use SemanticMerge as the merge tool, as described in the section below.
Once SemanticMerge is set as the merge tool for Git, when you trigger a merge in Visual Studio, get a conflict, and hit the 'Merge' button, SemanticMerge will open up, rather than Visual Studio's merge tool (which I've learnt from this process is called VSDiffMerge).
To configure SemanticMerge as the default merge tool for Git itself, edit the Git config file, either for a specific repository, or for all your repositories.
Before I messed with the global config file, I took a copy of its original state… you may or may not be this cautious!
This tells Git to use SemanticMerge as its merge tool.
cmd = C:/Users/Alice/AppData/Local/PlasticSCM4/semanticmerge/semanticmergetool.exe -d "$LOCAL" -s "$REMOTE" -b "$BASE" -r "$MERGED"
Obviously you will need to replace the path to the exe with whatever it is on your system.
There may already be a similar entry for another merge tool – it's fine to leave that in there.
Prompt = false prevents a prompt from appearing asking if you want to use an external merge tool each time you run the git mergetool command. It doesn't appear to affect merges prompted from Visual Studio. KeepBackup prevents Git from keeping '.orig' files, which are backup copies of files in their conflicted state.
git config --global mergetool.semanticmerge.cmd "C:/Users/Alice/AppData/Local/PlasticSCM4/semanticmerge/semanticmergetool.exe -d "$LOCAL" -s "$REMOTE" -b "$BASE" -r "$MERGED""
Oddly, I found that the mergetool.semanticmerge.cmd command didn't work when using PowerShell and Chocolately.
If you're using SmartGit to carry out a merge, when you get a merge conflict, right click on a conflicted file, and select Conflict Solver. If you've set up SemanticMerge as the default conflict solver, this will open the conflicted file in SemanticMerge.
Before the SemanticMerge window displays, you will see a pop up message from SmartGit asking if you want to stage the file. This is because the integration between SmartGit and a conflict solver is limited to SmartGit triggering the launch of the conflict solver together with the arguments we saw during set up – it has no way of knowing when you're done solving the conflict unless you tell it. Ignore the pop up for now and continue to SemanticMerge.
If you're using Visual Studio to carry out a merge, when you hit a merge conflict, click on the 'Resolve the conflicts' link, click on a conflicted file, and select the Merge button.
If you've configured Git to use SemanticMerge as the mergetool, then this will open up the conflicted file in SemanticMerge.
When SemanticMerge first opens, it displays summary page which lists the conflicts. Each conflicted structural element of the file is presented with a blue heading containing its name and type. Clicking on a heading expands a section below with information about the action in each branch which caused the conflict. If there's more than one conflict for the element, both conflicts are described. The full file is displayed to the right.
The view code options highlights the affected section in the file, and the diff option opens a diff between the base (common ancestor) and the branch.
If at this point you want to get a better understanding of the file and the conflict, you can use the Visual Merge option to see an interactive diagram of the differences between the conflicted files in the Visual merge window. The Visual Merge window presents the structure of the file being merged in a beautifully clean visual format, which can be filtered and drilled into. It displays a visualisation of the conflicted file, breaking it into namespace, using directives, class and class members.
Where there has been a change, the component affected is labelled with one of SemanticMerge's labels for the change type. Only those areas that have changed are displayed by default, though you can choose to show all structural elements of the file, or display an indication that there are unchanged sections.
To see a diff of the code for any elements displayed, you can select two elements in the visualisation, and click diff. For example, below I've selected the different versions of the original GetData method in the source and destination files to see a diff.
I find the visualisation very useful. Another nice thing about this tool is that the diff windows scroll at different speeds to keep the equivalent sections on screen.
At the moment, the visual merge window is purely for information, and you need to close it and go back to the main screen to carry out a merge. I'm finding it hard to fault SemanticMerge, but as a wishlist item, it would be excellent to be able to carry out merges from the visual merge window.
To resolve the conflict, close the visual merge window and go back to the main window. For some conflicts (such as a rename on both branches, or a change in one branch and a deletion in another), the only options available will be keep src or keep dst. The conflict is a simple either/ or.
For more complex conflicts, a merge option will be available. This opens Plastic SCM's XMerge, which is more like a traditional merge tool UI. (SemanticMerge can be configured to use other text merge tools). In addition to the source, destination and merged files, the base file is also shown.
The addition of the base file makes it sounds like the screen would be pretty crowded but the tool is visually clean and opens up with a focus on the first conflict, which is highlighted with a purple block over the line number. Conflicted areas are indicated by a red block in the margin between the panes, and changes which were automatically resolved are indicated with a grey block in the margin between the panes.
As with the other tools, you can navigate between conflicts using a tools pane with navigation arrows and the number of unresolved conflicts still waiting for resolution.
The results pane at the bottom of the window shows the conflicted line for source, base and destination, with colour coding to identify which version a line comes from.
Alternatively, you can edit the results pane directly to choose the combination of changes you want to keep.
Once you are happy with the changes, you click save and exit in the conflict solver window.
Back in SemanticMerge's main window, the conflict panel will show that the conflict is solved.
To return to your Git client, click save and close in SemanticMerge's main window.
If you triggered the merge in SmartGit, as this point, you need to hunt out the popup the first appeared when you opened SemanticMerge, and select to stage the newly resolved file.
Once you do this, the resolved file will be marked as staged, ready for a commit.
This process needs to be followed for each conflicted file you merge using SemanticMerge.
Finally click Commit, to complete the merge.
If you triggered the merge in Visual Studio, when you return to Visual Studio after working on a file, you will see a popup window asking if you want to accept the merged result.
This process needs to be followed for any conflicted files.
Once you've finished resolving the conflicts, click Commit Merge and enter a commit message to complete the merge.
I'll let you judge for yourself, but IMO this is a beautiful and useful tool.


such as all old people are sick or cranky or inflexible. They're not!
Our programs show how people in their 70s, 80s, and 90s are continuing their careers, starting new activities, exploring alternative life styles, and generally living life to the fullest within their capabilities.


You'll be cooking wholesome, flavourful, healthy dishes in this two-handled deep pan, designed to adapt the cooking "on stone" concept to every preparation. There'll be surprising results for both stewed and pan-seared food thanks to the performance provided by the Whitford "stone effect" interior coating.
Paint bottom. Average tickness 3,5 mm.


A nicely marked originalGerman WW2 leather holster for Large Frame Flare/ Signal pistols. It has a full flap cover with retaining starp & single alloy stud on the body. It has 2 rear belt loops & all leather and stitching are intact. The inside of the flap is nicely ink stamped by the manufacturer 'Josto Lederwarenfabrik, Franz Friedel, PragX' together with ' (Ausb kp 2/2/41). The back of the retaining strap is in stamped '42' and the rear of the body is faintly waffenamt. Price includes UK delivery. L 291.